Stockreport

Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Spyre Therapeutics, Inc.  (SYRE) 
PDF On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials  Part A readouts from SKYLINE platform trial in ulcerative colitis ("UC") [Read more]